Apyx Medical (NASDAQ:APYX) Rating Increased to Strong-Buy at Craig Hallum

Craig Hallum upgraded shares of Apyx Medical (NASDAQ:APYX) to a strong-buy rating in a research note issued to investors on Thursday morning, Zacks.com reports.

A number of other equities analysts also recently weighed in on APYX. JMP Securities reaffirmed a “market perform” rating on shares of Apyx Medical in a research note on Monday, September 16th. BTIG Research assumed coverage on shares of Apyx Medical in a research report on Thursday, October 17th. They issued a “neutral” rating on the stock.

Apyx Medical Stock Performance

APYX opened at $1.21 on Thursday. The stock’s 50 day moving average price is $1.22 and its two-hundred day moving average price is $1.34. The firm has a market capitalization of $41.92 million, a P/E ratio of -1.83 and a beta of 1.20. The company has a quick ratio of 4.45, a current ratio of 5.33 and a debt-to-equity ratio of 2.26. Apyx Medical has a 12-month low of $0.97 and a 12-month high of $3.26.

Apyx Medical (NASDAQ:APYX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). Apyx Medical had a negative return on equity of 105.45% and a negative net margin of 57.86%. The business had revenue of $12.15 million for the quarter, compared to analyst estimates of $12.67 million. During the same quarter in the prior year, the firm earned ($0.11) EPS. On average, equities analysts forecast that Apyx Medical will post -0.7 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Commonwealth Equity Services LLC increased its position in Apyx Medical by 2.9% during the 2nd quarter. Commonwealth Equity Services LLC now owns 511,561 shares of the company’s stock worth $685,000 after purchasing an additional 14,481 shares in the last quarter. Private Advisor Group LLC lifted its stake in shares of Apyx Medical by 3.9% in the third quarter. Private Advisor Group LLC now owns 322,321 shares of the company’s stock worth $400,000 after acquiring an additional 12,180 shares during the period. Rathbones Group PLC boosted its stake in shares of Apyx Medical by 148.0% in the 2nd quarter. Rathbones Group PLC now owns 251,334 shares of the company’s stock valued at $337,000 after purchasing an additional 150,000 shares during the last quarter. Perkins Capital Management Inc. boosted its position in Apyx Medical by 7.0% during the first quarter. Perkins Capital Management Inc. now owns 228,500 shares of the company’s stock valued at $311,000 after acquiring an additional 15,000 shares during the last quarter. Finally, RPg Family Wealth Advisory LLC bought a new stake in shares of Apyx Medical during the 2nd quarter valued at about $101,000. Institutional investors and hedge funds own 55.33% of the company’s stock.

Apyx Medical Company Profile

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.